Navigation Links
Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
Date:11/5/2007

1200 Q4w

treatment group achieved SVR, vs. 57.9% for peginterferon alfa-2a

administered every week.

-- In heavier patients (75 kg or heavier) who were treatment-adherent,

61.0% of those in the Albuferon 1200 Q4w treatment group achieved SVR,

versus 53.3% for peginterferon alfa-2a administered once every week.

-- Among all treatment-adherent patients in the Albuferon 1200 Q4w

treatment group, 62.0% achieved SVR, versus 66.7% for peginterferon

alfa-2a.

-- The rate of discontinuations due to adverse events was 12.1% in the

Albuferon 1200 Q4w treatment group, vs. 6.1% in the peginterferon alfa-

2a group. Adverse events observed were those typically expected with

interferon therapy.

-- The number of patients experiencing severe hematologic adverse events

was significantly lower in the Albuferon 1200 Q4w treatment group

(10.3%, vs. 20.2% for peginterferon alfa-2a, p<0.05).

Higher doses of Albuferon administered every four weeks, in combination with ribavirin, will be explored in a separate Phase 2b trial conducted by Novartis, which is expected to begin by year-end 2007.

About Albuferon

Albuferon is a novel long-acting form of interferon alpha created by HGS using its proprietary albumin fusion technology. Albuferon results from the genetic fusion of human albumin and interferon alpha. Human albumin is the most prevalent naturally occurring blood protein in the human circulatory system, persisting in circulation in the body for more than 20 days. Research shows that genetic fusion of therapeutic proteins to human albumin decreases clearance and prolongs the half-life of the proteins. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B and a number of cancers.

Albuferon is being developed by HGS and Novartis for the treatment of chronic hepatitis C under a worldwide co-development and commerci
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 2014 ,Weight Loss- Market Analysis, ... report provides comprehensive insights about phase III pipeline drugs ... of the report is to establish the understanding for ... across the different countries and regions. While the leading ... also provides details on the drug master filings across ...
(Date:8/18/2014)... Calif. , Aug. 18, 2014 ... therapeutics to treat infectious diseases, has announced intentions ... the treatment of the current Ebola Virus outbreak ... the use of GBV006, a combination of Food ... established compassionate use regulatory pathway.  The discovery of ...
(Date:8/18/2014)... 2014  Pharmacyclics, Inc. (NASDAQ: PCYC ) ... Tomasello as its Chief Commercial Officer.  Ms. Cline ... of the Americas, Hematology and Oncology, for the Celgene ... Prior to joining Celgene, Ms. Cline Tomasello was the ... Genentech, where she was responsible for over $1.7 billion ...
Breaking Medicine Technology:Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 4Globavir Seeking Approval and Launch of Novel Ebola Treatment Before Year End 2Globavir Seeking Approval and Launch of Novel Ebola Treatment Before Year End 3Globavir Seeking Approval and Launch of Novel Ebola Treatment Before Year End 4Pharmacyclics Appoints Chief Commercial Officer 2Pharmacyclics Appoints Chief Commercial Officer 3Pharmacyclics Appoints Chief Commercial Officer 4
... DELAND, Fla., May 13 USHIFU, LLC, the clinical ... pleased,to announce conditional written approval pending minor changes to ... for the treatment of,recurrent prostate cancer with the Sonablate(R) ... Dr. Herbert Lepor, Chairman of Urology at NYU ...
... Products Expand Infection Prevention Business, DUBLIN, Ohio, ... products and services that improve the safety and,productivity ... the,acquisition of assets of privately held Enturia, Inc., ... ChloraPrep(R) brand name., ChloraPrep(R) brand products are ...
Cached Medicine Technology:FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer 2Cardinal Health Completes Enturia Acquisition 2
(Date:8/19/2014)... LunaDress, a popular supplier of fashionable ... ladies, is now providing a discount of up to ... company’s cheap white prom outfits are available in different ... outfits. , There are over 400 cheap white ... the special offer is valid until August 29, 2014. ...
(Date:8/19/2014)... (PRWEB) August 20, 2014 Recently, iFitDress.com,a ... occasion outfits, has unveiled its new collection of ... made to expand the company’s global market. Each item ... to the company’s senior spokesman, customers that have specific ... at iFitDress.com. Now, all the brand new items are ...
(Date:8/19/2014)... 2014 The National Cannabis Industry ... Southwest CannaBusiness Symposium on Saturday, August 23, from ... in Las Vegas. , Featuring keynotes by U.S. Representative ... (D-Las Vegas), the event will also include in-depth discussions ... NCIA is doing federally to advance a legitimate and ...
(Date:8/19/2014)... Drews Dental Services is proud to announce the recent election ... Maine Dental Association (MDA). After serving on the Executive Board ... been sworn in to his new position. , Dr. Drews ... and being a part of the ADA House of Delegates ... 2015. He plans to advocate for the profession of dentistry ...
(Date:8/19/2014)... Tara Haelle HealthDay ... -- Kidney injury can be added to the list ... medications often prescribed to treat behavioral symptoms of dementia ... (Seroquel), risperidone (Risperdal) and olanzapine (Zyprexa) are approved by ... disorder, schizophrenia and other serious mental disorders. They are ...
Breaking Medicine News(10 mins):Health News:Popular Supplier LunaDress Providing an Exclusive Assortment of White Prom Dresses at a Discount of Up to 67% 2Health News:Discounted Pewter Evening Dresses For 2014 Unveiled By Company iFitDress.com 2Health News:SATURDAY IN LAS VEGAS: U.S. Rep. Dina Titus, State Sen. Tick Segerblom Keynote National Cannabis Industry Association Southwest CannaBusiness Symposium 2Health News:Dr. Drews Elected VP of Maine Dental Association 2Health News:Certain Antipsychotic Meds Tied to Kidney Problems in Elderly 2Health News:Certain Antipsychotic Meds Tied to Kidney Problems in Elderly 3
... Five former directors of the Population and Reproductive Health ... (USAID) today urged the new Obama administration to move ... . The former directors issued a joint report, ... Assistance, as Barack Obama takes office as president. ...
... K. Shinseki took the oath of office today as ... leadership of the Department of Veterans Affairs following Tuesday,s ... from my first day in office is to make ... focused on the Nation,s Veterans as its clients," Shinseki ...
... 21 The following statement can be attributed ... BlueCross:"Capital BlueCross has consistently said two things: We ... other merger. But we have urged public policy ... this proposed merger without conditions, because without conditions ...
... low levels of sexual desire, often as a result of ... physical symptoms such as back pain and memory problems than ... new study by researchers at the University of North Carolina ... study, published recently as an online early view article in ...
... history was made 10 years ago, greatly impacting the ... when a team of surgeons performed the first hand ... procedure, also called composite tissue allotransplantation, criticized by some ... in the world of organ transplantation, has continued to ...
... IDEXX Laboratories, Inc. (Nasdaq: IDXX ), has scheduled ... results for Friday, January 30, at approximately 7:00 a.m. (eastern). ... 9:00 a.m. (eastern) on that day. Individuals can access a ... the IDEXX Web site, www.idexx.com . An archived edition ...
Cached Medicine News:Health News:Five Former USAID Officials Ask Obama for Leadership on Family Planning 2Health News:Shinseki Sworn In, Vows 21st Century Service to Veterans 2Health News:Capital Blue Cross Issues Statement on Withdrawal of Merger 2Health News:UNC study: Postmenopausal women's loss of sexual desire affects health, quality of life 2Health News:Hand Transplantation Marks Historical 10-Year Milestone 2Health News:Hand Transplantation Marks Historical 10-Year Milestone 3Health News:Hand Transplantation Marks Historical 10-Year Milestone 4
... The Awaya stereo test was developed to ... Awaya Stereo test employs the more reliable ... eye. It is not dependent on polarizing spectacles ... first target is an attractive image of a ...
... is designed to assist patients with red-green color ... filter cuts off wavelengths shorter than 582 nm ... of their most difficult color distinctions. A color ... determine whether a color is in the longer ...
Features a twist-on backswitch, with a diffused, cobalt blue light beam....
Heavy duty, all purpose illuminator available in blue and green. Unique Clip Switch automatically turns off when returned to pocket. Pre-focused lens tip Heine XHL Halogen bulb for bright, concentra...
Medicine Products: